Mantle Cell Lymphoma Therapeutics Market Size, Share, and Industry Analysis By Therapy (Chemoimmunotherapy, Targeted Therapy, and Others), By Drug Class (Bruton\'s Tyrosine Kinase Inhibitors (BTKIs), Monoclonal Antibodies, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Mantle cell lymphoma is a rare type of blood cancer that begins in the B lymphocytes present in the mantle zones of lymph nodes. This cancer is classified as non-Hodgkin lymphoma and often begins as a slow-growing condition that later grows aggressively. The aggressive form can spread to other parts of lymph nodes, bone marrow, bloodstream, and digestive system. Chemoimmunotherapy is considered a frontline therapy for mantle cell lymphoma and is followed by targeted therapy. Currently, chemoimmunotherapy is a combination of chemodrugs, an immunomodulatory agent, and a steroid.

The market for mantle cell lymphoma therapeutics is witnessing significant growth across the globe. The key factors attributed to the market growth are the increasing number of drug approvals for the treatment, the rising number of clinical trials, and the awareness related to cancer diagnosis. In addition, technological advancements in the drug discovery process, such as using artificial intelligence to identify drug targets, accelerate the approval rate of new drugs and drive the market growth.

• In March 2023, Lantern Pharma Inc. initiated a phase 1 clinical trial for LP-284. The drug had been developed with guidance from the company's AI platform, RADR, as a potential therapy for relapsed or refractory non-Hodgkin's lymphoma, including mantle cell lymphoma.

Globally, an increase in the number of collaborations for drug discovery and clinical trials and a promising pipeline are anticipated to further boost the market growth in the near future. Moreover, the strategic investments of major players in the clinical stage companies could drive the pipeline and new drug launches in the market.

The COVID-19 pandemic substantially impacted the market due to travel restrictions and worldwide lockdowns. The market growth was affected by supply chain disruptions across the globe. The number of patients visiting hospitals declined during the pandemic, which further declined the diagnosis and treatment of mantel cell lymphoma. However, the post-pandemic relaxation of restrictions increased the diagnosis and treatment of this disease, significantly driving the market growth.

Key Insights

• Pipeline Analysis, By Key Players
• New Product Launches, By Key Players
• Prevalence of Mantle Cell Lymphoma, By Key Countries/ Region, 2023
• Key Industry Developments - Mergers, Acquisitions, Partnerships, and Others
• Impact of COVID-19 on the Market

Segmentation

Analysis by Therapy

Based on therapy, the market is segmented into chemoimmunotherapy and targeted therapy. The chemoimmunotherapy held a significant market share in 2023. Chemotherapy drugs in combination with immunotherapy or steroid drugs are considered a common regimen for the mantle cell lymphoma. In most practices, R-CHOP (rituxan, cyclophosphamide, hydroxydaunomycin (doxorubicin), oncovin (vincristine), and prednisone) combination is administered for the management of mantle cell lymphoma.

The high potency of these combinations and well-established clinical evidence increase the usage of these drugs and enable the segment to hold a significant share of the market. Furthermore, an increasing number of clinical trials for specific chemotherapy agents is expected to drive segment growth.

The targeted therapy segment is anticipated to grow rapidly during the forecast period. The growth in the number of targeted drug approvals, rising R&D investments, and technological advancements in drug discovery are expected to accelerate the adoption of target therapy drugs.

• For instance, in November 2019, BeiGene, Ltd. received the U.S. FDA approval for BRUKINSA (zanubrutinib). It is a Bruton's Tyrosine Kinase Inhibitors (BTKIs) for the treatment of mantle cell lymphoma. In addition, the player's strategic collaboration for drug development and commercialization is further expected to boost segment growth in the near future.

Regional Analysis

In terms of region, North America accounted for a significant share of the market in 2023. The region's high prevalence of mantle cell lymphoma and earlier approval of advanced drugs for the treatment are the key factors anticipated to contribute to the dominance. Moreover, the presence of major players, a rapidly growing number of clinical trials, and technological advancements that speed up the drug discovery process are anticipated to propel the regional growth.

• For instance, an article published in the American Journal of Hematology in March 2022 stated that Mantle cell lymphoma the of mantle cell lymphoma is 4 to 8 cases per million per year and the rate of incidence appears to be rising in the U.S. The growth in the incidence and availability of earlier detection methods in the region is expected to boost the market.

The Asia Pacific region is expected to witness rapid growth over the coming years. The acceleration in the number of cancer diagnoses and the increased number of collaborations for drug developments in the region are the key factors expected to drive the segmental growth. Moreover, the rising governmental initiatives for early disease diagnosis and growth in the awareness among the general population is expected to boost the market in the near future.

Key Players Covered

The report includes the profiles of key players such as BeiGene, Ltd., AbbVie Inc., Johnson & Johnson Services, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, AstraZeneca, Bristol-Myers Squibb Company, and Azurity Pharmaceuticals, Inc.

Key Industry Developments

• In December 2023, CSTONE PHARMACEUTICALS published preliminary results of phase 1 clinical drug candidate CS5001. The results suggested the safety, stability, and anti-tumor activity of CS5001 in various hematological and solid malignancies, including mantle cell lymphoma.
• In January 2023, Schrödinger, Inc. initiated a phase 1 clinical trial for the SGR-1505, an oral inhibitor of MALT1 to treat mantle cell lymphoma. The drug was developed using the proprietary AI technology of Schrödinger, Inc.

In November 2020, Merck & Co., Inc. acquired VelosBio to strengthen its oncology pipeline. Through the acquisition, the company acquired zilovertamab vedotin, a phase 2 clinical candidate to treat hematological malignancies, including mantle cell lymphoma.